Keros Therapeutics (NASDAQ:KROS) Sees Strong Trading Volume – Still a Buy?

Keros Therapeutics, Inc. (NASDAQ:KROS) shares saw unusually-strong trading volume on Friday . Approximately 923,607 shares were traded during mid-day trading, an increase of 110% from the previous session’s volume of 439,983 shares.The stock last traded at $19.67 and had previously closed at $18.43.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Jefferies Financial Group assumed coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. Guggenheim restated a “buy” rating and issued a $102.00 price target (up from $96.00) on shares of Keros Therapeutics in a research note on Wednesday, December 4th. HC Wainwright cut their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research report on Friday. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $89.33.

Keros Therapeutics Stock Performance

The stock has a market cap of $728.72 million, a P/E ratio of -3.57 and a beta of 1.20. The firm’s fifty day simple moving average is $59.95 and its 200-day simple moving average is $52.83.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million during the quarter. During the same quarter last year, the firm posted ($1.33) EPS. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year. Analysts predict that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KROS. FMR LLC boosted its holdings in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after buying an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC boosted its stake in Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after acquiring an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. grew its holdings in Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after purchasing an additional 89,952 shares during the period. Point72 Asset Management L.P. increased its stake in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP raised its holdings in shares of Keros Therapeutics by 22.5% during the third quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock valued at $48,959,000 after purchasing an additional 154,784 shares during the period. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.